Botanix Pharmaceuticals Dividends and Buybacks
Dividend criteria checks 0/6
Botanix Pharmaceuticals does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-58.5%
Buyback Yield
| Total Shareholder Yield | -58.5% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
Recent updates
BOT: Commercial Launch Execution Will Drive Future Upside Potential
Analysts have reset their price expectations for Botanix Pharmaceuticals, cutting the fair value estimate from A$0.21 to A$0.14. They cite updated assumptions for discount rate, revenue growth, profit margins, and a lower future P/E multiple.
BOT: Future Share Dilution From Large Capital Raising Will Drive Upside Potential
Analysts have reset their fair value estimate for Botanix Pharmaceuticals from A$0.83 to A$0.49, reflecting updated assumptions for the discount rate, revenue growth, profit margins, and a much lower future P/E multiple. What's in the News Botanix Pharmaceuticals completed a follow on equity offering of A$4.999999 million in ordinary shares, comprising 14,341,646 securities at A$0.06 each with attached options, plus an additional 68,991,667 ordinary shares at A$0.06 each with attached options.
Bullish View That A Scalable Dermatology Platform Will Transform An Underserved Hyperhidrosis Market
Catalysts About Botanix Pharmaceuticals Botanix Pharmaceuticals is a dermatology company focused on commercialising Sofdra for primary axillary hyperhidrosis and leveraging its U.S. commercial platform. What are the underlying business or industry changes driving this perspective?Single Product And API Constraints Will Shape Dermatology Platform Potential Over The Long Term
Catalysts About Botanix Pharmaceuticals Botanix Pharmaceuticals is a dermatology company focused on Sofdra, a prescription treatment for primary axillary hyperhidrosis supported by its own fulfillment platform. What are the underlying business or industry changes driving this perspective?Long-Term Hyperhidrosis Demand And Fulfillment Platform Will Support This Bullish Thesis
Catalysts About Botanix Pharmaceuticals Botanix Pharmaceuticals is a dermatology company focused on Sofdra, a prescription treatment for primary axillary hyperhidrosis. What are the underlying business or industry changes driving this perspective?Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Botanix...Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Here's Why We're Watching Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Botanix Pharmaceuticals (ASX:BOT) Will Have To Spend Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...Can Botanix Pharmaceuticals (ASX:BOT) Afford To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...We're Not Very Worried About Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...We Think Botanix Pharmaceuticals (ASX:BOT) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Botanix Pharmaceuticals...We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...The Botanix Pharmaceuticals (ASX:BOT) Share Price Has Gained 81% And Shareholders Are Hoping For More
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But one can do...We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if BOT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BOT's dividend payments have been increasing.
Dividend Yield vs Market
| Botanix Pharmaceuticals Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (BOT) | n/a |
| Market Bottom 25% (AU) | 2.7% |
| Market Top 25% (AU) | 6.7% |
| Industry Average (Pharmaceuticals) | 2.2% |
| Analyst forecast (BOT) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate BOT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BOT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate BOT's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BOT has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/14 04:32 |
| End of Day Share Price | 2026/07/14 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Botanix Pharmaceuticals Limited is covered by 2 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madeleine Williams | Canaccord Genuity |
| Joseph Pantginis | H.C. Wainwright & Co. |